You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR NASALCROM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NASALCROM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01175525 ↗ Treatment of Acute Stroke With Cromolyn(Single Dose) Unknown status Wolfson Medical Center Phase 3 1969-12-31 Mastocytes were proven to have a central rule in their development of the lipoid plaque of the vascular system. Mastocytes also has an important role in the stabilisation of the plaque in the building of the brain barrier. Different animal studies show that the inhibition of the mastocyte activity decreases significantly the risk of secondary bleeding post ischaemic stroke.It was also shown that post stroke inflammation process was also blocked by the inhibition of mastocytes.Other studies showed up to 100% decrease in the brain barrier disruption and post stroke oedema, after treatment with mastocyte inhibitors. Cromolyn is a synthetic drug which has an anti-allergic effect by inhibition of the mastocytes. This drug is a well known,safe drug and is the main sub-substance that was used in the previously mentioned studies.
NCT03794076 ↗ Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia Recruiting Stanley Medical Research Institute Phase 1/Phase 2 2019-04-01 This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.
NCT03794076 ↗ Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia Recruiting Vishwajit Nimgaonkar, MD PhD Phase 1/Phase 2 2019-04-01 This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NASALCROM

Condition Name

Condition Name for NASALCROM
Intervention Trials
Acute Stroke 1
Schizo Affective Disorder 1
Schizophrenia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NASALCROM
Intervention Trials
Schizophrenia 1
Psychotic Disorders 1
Mood Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NASALCROM

Trials by Country

Trials by Country for NASALCROM
Location Trials
United States 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NASALCROM
Location Trials
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NASALCROM

Clinical Trial Phase

Clinical Trial Phase for NASALCROM
Clinical Trial Phase Trials
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NASALCROM
Clinical Trial Phase Trials
Recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NASALCROM

Sponsor Name

Sponsor Name for NASALCROM
Sponsor Trials
Wolfson Medical Center 1
Stanley Medical Research Institute 1
Vishwajit Nimgaonkar, MD PhD 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NASALCROM
Sponsor Trials
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.